$83.33+2.38%Close 13 Nov 2026 · Market value $30.72B
In its results release of 29 Oct 2026 (Q3 FY2026), Dexcom gave 4 forecasts in figures, among them revenue of $5.20B to $5.25B for FY2026. Over the last two years, results landed above the company's own last range 1 of 6 times, within it 3 and below it 2.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q3 FY2026 results, 29 Oct 2026
| Measure | Period | Guidance | As stated |
|---|
| Revenue | FY2026 | $5.20B to $5.25B | Revenue of $5.20 - $5.25 billion (approximately 12-13% growth) |
|---|
| Revenue growth | FY2026 | About +12% to +13% | Revenue of $5.20 - $5.25 billion (approximately 12-13% growth) |
|---|
| Gross margin · Adjusted | FY2026 | About 64% | Non-GAAP Gross Profit Margin of approximately 64% |
|---|
| Operating margin · Adjusted | FY2026 | About 24% | Non-GAAP Operating Margin of approximately 24% |
|---|
Source: the company's earnings release.
Guidance against results above 1 · within 3 · below 2
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Revenue | FY2026 | $5.20B to $5.25B | Raised twice | — | To come |
|---|
| Revenue growth | FY2026 | About +12% to +13% | Raised once | — | To come |
|---|
| Gross margin · Adjusted | FY2026 | About 64% | Raised once | — | To come |
|---|
| Operating margin · Adjusted | FY2026 | About 24% | Raised 3 times | — | To come |
|---|
| Revenue | FY2025 | $4.63B to $4.65B | Raised twice | $4.66B | Above the range |
|---|
| Revenue growth | FY2025 | About +15% | Given once | +15.6% | Above the range |
|---|
| Gross margin · Adjusted | FY2025 | About 61% | Lowered twice | 60.8% | Within the range |
|---|
| Operating margin · Adjusted | FY2025 | About 20% to 21% | Lowered once | 20.8% | Within the range |
|---|
| Revenue | FY2024 | About $4.00B to $4.05B | Given once | $4.03B | Within the range |
|---|
| Gross margin · Adjusted | FY2024 | About 63% | Given once | 61.8% | Below the range |
|---|
| Operating margin · Adjusted | FY2024 | About 20% | Given once | 18.8% | Below the range |
|---|
DXCM in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.